ARDS · Categories · M&A
ARDS - Mergers and acquisitions
Aridis Pharmaceuticals Inc. (ARDS) mergers and acquisitions - real-time wire coverage filtered to M&A only.
Recent M&A for ARDS
- Aridis Signs Exclusive Terms to Secure Worldwide Commercial Licenses for Pan-Ebola and Pan-Marburg Monoclonal Antibody Programs from Mapp BiopharmaceuticalThe Sudan Ebola and Marburg mAb programs were awarded approximately $190 million of BARDA funding covering manufacturing, efficacy and safety evaluations, and regulatory approval Los Gatos, Calif., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, signed an exclusive term sheet to secure international development and global commercial rights upon licensure for the pan-Ebola and pan-Marburg monoclonal antibody (mAbs) programs from Mapp Biopharmaceutical, Inc. (MappBio), a privately-owned leading developer of novel pha
- Aridis Pharmaceuticals Announces Exclusive License of Suvratoxumab, a Phase 3-Ready Monoclonal Antibody, from AstraZenecaLOS GATOS, Calif., July 19, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) today announced that it has entered into an exclusive, worldwide licensing agreement with AstraZeneca (NASDAQ:AZN) to in-license the late stage monoclonal antibody candidate, suvratoxumab. The highlights of the agreement are: Phase 3-ready candidate. Suvratoxumab monoclonal antibody (mAb) for prevention of pneumonia has been licensed from AstraZeneca. Suvratoxumab extends Aridis' pneumonia franchise by complementing the existing AR-301 Phase 3 pneumonia treatment program. Lancet ID publication. Phase 2 data involving n=196 patients recently published in The Lancet Infectious Diseases journal showed